OMNIA-1, a Phase I/II study of ANV419, an IL- 2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma
Search here
Categories
Recent Posts
Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual Meeting
June 5, 2023Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual Meeting
June 3, 2023Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual Meeting
April 18, 2023
Popular Tags
Archives
- June 2023 2
- April 2023 1
- March 2023 2
- February 2023 1
- November 2022 2
- October 2022 1
- September 2022 1
- July 2022 3
- April 2022 1
- March 2022 1
- December 2021 1
- November 2021 1
- June 2021 1
- March 2021 1
- November 2020 1
- May 2020 1
- April 2019 1
- February 2019 1